Pre-ECCMID day on COVID-19 (Part Two)

Don’t miss the next live Pre-ECCMID day, starting tomorrow from 08:15 CEST on the ECCMID online platform.

View the full programme and register on the ECCMID website. Remember that your full ECCMID registration includes access to all of the Pre-ECCMID days, as well as the on-demand recordings of all the previous ones.

› Read more

ECCMID 2021 Top Rated ePosters

At previous ECCMIDs, the top rated posters were easily identifiable by the ribbons which were affixed to them.

For the first ever fully online ECCMID, we are excited to again draw attention to the top rated ePosters, and to highlight the outstanding work done by the authors.

The top rated ePosters can be identified in the ePoster programme by the red ribbon icon, and session times will be available in which you can talk live to the presenting authors on Monday, 12 July 2021!

Find out more in the ECCMID website.

› Read more

Open call to join the CMI editorial team: editor in clinical microbiology

Clinical Microbiology and Infection (CMI), the official publication of ESCMID, is looking for an editor in clinical microbiology to join their editorial team. The new editor will need to deal mainly with diagnostic clinical microbiology techniques, both classical and new molecular ones; in bacterial, viral and fungal infections.

CMI editors participate in making decisions on the journals' policies, attend meetings, invite peer-reviewers, and much more. The appointment is for four years but can be extended and can be a very rewarding experience! You can learn more about the position and how to apply on the ESCMID website.

Applications are open until September 15th, 2021

› Read more

Public Consultation is open for the “European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults” draft manuscript

If you wish to comment on the manuscript, please write to guidancedocuments@escmid.org indicating their ESCMID membership number.

You will receive the confidential manuscript, along with the comments form for listing feedback and the together with the template to register their comments and the AGREE GLOBAL RATING SCALE form to be completed (More information about the AGREE II tool can be found here).

Please note that by accepting to participate to the Public Consultation Phase, you agree to commit to confidentiality and to respond within the deadline.

The deadline to provide feedback and comments is 5 July 2021.

› Read more

EMA communication: Veterinary Medicines Regulation Highlights - May 2021 - issue 5

Find here the latest edition of the Veterinary Medicines Regulation Highlights, which provides updates on the progress at the Agency towards implementing Regulation (EU) 2019/6. The Newsletter is published every two months.

You can access the Newsletter by clicking here. Previous editions can be found on this page.

Please feel free to disseminate this Newsletter to anyone else who might be interested in this information.

› Read more

COMBACTE Poster and Presentation Platform

COMBACTE is continuously working on sharing science with the public on the combat on Antimicrobial Resistance. As part of disseminating their results, COMBACTE created the COMBACTE Poster and Presentation Platform. The platform includes the most recent study updates across COMBACTE-NET, COMBACTE-MAGNET and COMBACTE-CARE projects. All updates are available as short videos presented by members of COMBACTE studies or networks.

› Read more

EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome

EMA’s COVID-19 taskforce (COVID-ETF) is advising healthcare professionals in the EU to consider recommendations by learned societies when assessing people with signs and symptoms of thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria and COVID-19 Vaccine Janssen. In this context it is highlighting guidance from the International Society on Thrombosis and Haemostasis (ISTH).

The advice from the taskforce follows EMA’s review of TTS, a very rare event following vaccination with Vaxzevria and COVID-19 Vaccine Janssen. The conclusions reached are based on EMA’s safety signal evaluations, which led to updates of the product information for both Vaxzevria and COVID-19 Vaccine Janssen. Healthcare professionals have been informed through direct healthcare professional communications (DHPCs) of the signs and symptoms of TTS with either vaccine, so that people affected can be diagnosed and treated as soon as possible using the available guidelines.

EMA recognises and supports the extensive work by healthcare professionals and learned societies, which is essential to optimise the management of people with suspected TTS following vaccination with Vaxzevria or COVID-19 Vaccine Janssen.

For more details, please refer to the published news. Please check EMA’s dedicated webpage on COVID-19 for the latest updates.

› Read more

CMI highlight: National surveillance of bacterial and fungal co- and secondary infection in COVID-19 patients in England – Lessons from the first wave

The impact of bacterial/fungal infections on the morbidity and mortality of persons with COVID-19 remains unclear. The authors of this publication have investigated the incidence and impact of key bacterial/fungal infections in COVID-19 persons in England, analysing laboratory-confirmed SARS-CoV-2 cases and blood and lower-respiratory specimens positive from Public Health England’s national laboratory surveillance system.

It emerged that co/secondary bacterial/fungal infections were rare in non-hospitalised and hospitalised persons with COVID-19, varied by ethnicity and age, and were associated with higher mortality. However, the inclusion of non-hospitalized persons with asymptomatic/mild COVID-19 likely underestimated the rate of secondary bacterial/fungal infections. This should inform diagnostic testing and antibiotic prescribing strategy.

› Read more